指南与共识甲状腺疾病

超声引导下细针穿刺良性甲状腺结节的随访策略:Bethesda系统前后管理指南的恶性率

Follow-Up Strategies for Thyroid Nodules with Benign Cytology on Ultrasound-Guided Fine Needle Aspiration: Malignancy Rates of Management Guidelines Using Ultrasound Before and After the Era of the Bethesda System.
指南 / 共识 · Thyroid · 2019-08-28

该回顾性研究纳入1716个初始细针穿刺细胞学良性的甲状腺结节,比较Bethesda系统前后时期及四种指南风险分层下的恶性率。Bethesda前后恶性率分别为3.2%和2.6%(p=0.641);Bethesda后时期2015 ATA高度可疑模式和ACR-TIRADS 5类的估计恶性率>5%。结论认为良性细胞学诊断后立即诊断干预可能不必要,但高可疑类别可考虑。

要点

  • Bethesda系统前后良性结节恶性率无显著差异(3.2% vs 2.6%,p=0.641)。
  • Bethesda后时期2015 ATA高度可疑和ACR-TIRADS 5类估计恶性率>5%。
  • 良性细胞学后立即干预可能不必要,但高可疑类别可考虑。

核心结论

  • 良性细胞学诊断后立即诊断干预可能不必要,但2015 ATA高度可疑或ACR-TIRADS 5类可考虑。

研究设计与样本

  • 回顾性研究,纳入1716个初始超声引导下细针穿刺细胞学良性的甲状腺结节(1695例患者),其中Bethesda前1187个、Bethesda后529个。

主要发现

  • Bethesda前时期恶性率为3.2%(38/1187),Bethesda后时期为2.6%(14/529),p=0.641。
  • Bethesda后时期2015 ATA高度可疑模式和ACR-TIRADS 5类的估计恶性率>5%,分别为6.52和8.57。
  • ACR-TIRADS中提示行细针穿刺的阳性发现估计恶性率分别为5.26和5.67,其余指南两个时期估计恶性率均<5%。

关键数值与推荐

  • 2015 ATA高度可疑模式在Bethesda后时期估计恶性率为6.52。
  • ACR-TIRADS 5类在Bethesda后时期估计恶性率为8.57。
  • ACR-TIRADS中提示行细针穿刺的阳性发现估计恶性率分别为5.26和5.67。
  • 其余指南在两个时期估计恶性率均<5%。

临床怎么用

  • 对细胞学良性甲状腺结节,可避免立即诊断干预,但应结合2015 ATA或ACR-TIRADS高可疑类别评估是否进一步干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: To evaluate differences in malignancy rates and consequent follow-up strategies for cytologically benign thyroid nodules before and after the introduction of the Bethesda system according to the risk stratification categories of four thyroid management guidelines. Methods: This retrospective study was approved by our institutional review board. In this study, 1716 thyroid nodules with initially benign cytologic diagnosis at ultrasound-guided fine needle aspiration (US-FNA) in 1695 patients were included: 1187 nodules from the pre-Bethesda period and 529 nodules from the post-Bethesda period. Based on US features, the thyroid nodules were categorized into the final assessment categories of the 2015 American Thyroid Association (ATA), the 2016 American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi, the American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS), and the European Thyroid Association guidelines for Ultrasound Malignancy Risk Stratification systems. Estimated malignancy rates before and after propensity score matching according to follow-up intervals were obtained. Results: Of the 1716 thyroid nodules benign on initial US-FNA, the malignancy rate was 3.2% (38 of 1187) in the pre-Bethesda period and 2.6% (14 of 529) in the post-Bethesda period (p = 0.641). The 2015 ATA high suspicion pattern and the ACR-TIRADS category 5 had high estimated malignancy rates of >5% in the post-Bethesda period (6.52 and 8.57, respectively). Positive findings that indicated US-FNA in the ACR-TIRADS had estimated malignancy rates of 5.26 and 5.67, respectively, while the remaining guidelines had estimated malignancy rates of <5% in both periods. Conclusions: Immediate diagnostic intervention after benign cytologic diagnosis may not be necessary regardless of the cytologic criteria applied, but it can be considered for the highly suspicious categories in the 2015 ATA or the ACR-TIRADS for benign cytologic diagnosis of the Bethesda system.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Yoon JH, Lee HS, Kim EK, et al. Follow-Up Strategies for Thyroid Nodules with Benign Cytology on Ultrasound-Guided Fine Needle Aspiration: Malignancy Rates of Management Guidelines Using Ultrasound Before and After the Era of the Bethesda System. Thyroid. 2019. PMID: 31359839. doi:10.1089/thy.2018.0769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。